Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

METHODS OF CANCER TREATMENT BY INHIBITION OF VASCULOGENESIS AND GLI1

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • Publication Date:
    November 24, 2022
  • معلومة اضافية
    • Document Number:
      20220372486
    • Appl. No:
      17/742126
    • Application Filed:
      May 11, 2022
    • نبذة مختصرة :
      The present invention relates to methods and systems for a delay in the onset of early osteogenic markers, a reduction in the hematopoietic potential to form granulocyte units, and a decrease in vascular potential and in cancer-related gene expression. The present invention is a method of down-regulation of GLI1 via CRISPR or siRNA. The present invention indicates that the GLI1 intronic region is critical for the feedback loop and that GLI1 has lineage-specific effects on hESC differentiation. The present invention documents the extent of GLI1 abrogation on early stages of human development and to show that GLI1 transcription can be altered in a therapeutically useful way.
    • Claim:
      1. A method of suppressing expression of GLI1 gene in a cell, said method comprising subjecting said cell using a CRISPR-Cas editing system and a guide RNA (gRNA) to generate suppress expression of GLI1; and treating a disease or disorder in a subject by administering to the subject a therapeutically effective amount of the GLI1 suppressed cell.
    • Claim:
      2. The method of claim 1, wherein the disease or the disorder is an infection, a cancer, a vascular disease.
    • Claim:
      3. The method of claim 2, wherein the cancer is a type of solid cancer, type of glioblastoma.
    • Claim:
      4. The method of claim 3, wherein the infection is a bacterial infection or a viral infection.
    • Claim:
      5. The method of claim 4, further comprising eliminating GLI1 positive feedback loop in hPSCs.
    • Claim:
      6. A method of treating a disease or disorder in a subject in need thereof comprising administering to a siRNA comprising the sequence selected from SEQ ID NO: 1-6 to generate a GLI modified cell; and treating a disease or disorder in a subject by administering to the subject a therapeutically effective amount of the GLI1 modified cell to treat the disease or disorder.
    • Claim:
      7. The method of claim 6, wherein the disease or the disorder is an infection, a cancer, a vascular disease.
    • Claim:
      8. The method of claim 7, wherein the cancer is a type of solid cancer, type of glioblastoma.
    • Claim:
      9. The method of claim 8, wherein the infection is a bacterial infection or a viral infection.
    • Claim:
      10. The method of claim 10, further comprising downregulating cancer-related gene expression to prevent tumor angiogenesis.
    • Current International Class:
      12; 61; 61; 61
    • الرقم المعرف:
      edspap.20220372486